Biotech Values

[genisi]

Bapinuzumab showed a 25% reduction in total tau and phosphotau in ph 2 that was very near statisitical significancee with a small sample size.

Bapineuzumab phase II data (as presented at the ICAD 2008), showed a trend toward lower phospho-tau in CSF of treated versus placebo with p=0.056, which I agree is evidence for its biological activity. However, CSF Aß and total tau were the same between treated and placebo groups.